THE EFFECT OF ABIRATERONE ON THE METABOLISM OF OXYCODONE (ENABLE study)

You likely can't join if

• - A body mass index (BMI) outside the range of 18 – 30 kg/m2; - If hypersensitive to oxycodone; patients suffering from diarrhoea and/or opioid withdrawal; - If any type of abnormality; active or symptomatic viral hepatitis or chronic liver disease (e.g. classification with Child-Pugh B, Child-Pugh C); - Known metastases in the liver that would affect drug metabolism; - Patients with a CYP3A4 or CYP2D6 polymorphism; - Moderate-severe renal dysfunction (GFR <60 ml/min/1.73m2) that affects drug metabolism ; - Arm 1: dose reduction or successive days of treatment interruption within 10 days prior to the study day (arm 1); - Arm 2: treatment with abiraterone within 10 days prior to the study day; - Subjects with significant respiratory depression, acute or severe bronchial asthma or hypercarbia; - If subjects started first cycle of chemotherapy during the 2 weeks before the screening visit - Major surgery within 1 month prior to screening or planned surgery; - Severe Chronic obstructive pulmonary disease, pulmonary heart disease; - Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine); - Patients with evidence of clinically significant gastrointestinal disease; - Patients who are contraindicated for blood sampling; - Unable to swallow solid, oral dosage forms whole with water; - Participation in a clinical trial study at the time of enrolment or within 30 days or 5 half-lives of enrolment, whichever is longer; - Previous gastric bypass or gastric band surgery.